Találati lista | Tudóstér

001-es BibID:	BIBFORM020688
Első szerző:	Barrett-Connor, Elizabeth
Cím:	Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women / Barrett-Connor E., Mosca L., Collins P., Geiger M. J., Grady D., Kornitzer M., McNabb M. A., Wenger N. K., the Raloxifene Use for The Heart (RUTH) Trial Investigators
Dátum:	2006
Megjegyzések:	The effect of raloxifene, a selective estrogen-receptor modulator, on coronary heart disease (CHD) and breast cancer is not established. METHODS: We randomly assigned 10,101 postmenopausal women (mean age, 67.5 years) with CHD or multiple risk factors for CHD to 60 mg of raloxifene daily or placebo and followed them for a median of 5.6 years. The two primary outcomes were coronary events (i.e., death from coronary causes, myocardial infarction, or hospitalization for an acute coronary syndrome) and invasive breast cancer. RESULTS: As compared with placebo, raloxifene had no significant effect on the risk of primary coronary events (533 vs. 553 events; hazard ratio, 0.95; 95 percent confidence interval, 0.84 to 1.07), and it reduced the risk of invasive breast cancer (40 vs. 70 events; hazard ratio, 0.56; 95 percent confidence interval, 0.38 to 0.83; absolute risk reduction, 1.2 invasive breast cancers per 1000 women treated for one year); the benefit was primarily due to a reduced risk of estrogen-receptor-positive invasive breast cancers. There was no significant difference in the rates of death from any cause or total stroke according to group assignment, but raloxifene was associated with an increased risk of fatal stroke (59 vs. 39 events; hazard ratio, 1.49; 95 percent confidence interval, 1.00 to 2.24; absolute risk increase, 0.7 per 1000 woman-years) and venous thromboembolism (103 vs. 71 events; hazard ratio, 1.44; 95 percent confidence interval, 1.06 to 1.95; absolute risk increase, 1.2 per 1000 woman-years). Raloxifene reduced the risk of clinical vertebral fractures (64 vs. 97 events; hazard ratio, 0.65; 95 percent confidence interval, 0.47 to 0.89; absolute risk reduction, 1.3 per 1000). CONCLUSIONS: Raloxifene did not significantly affect the risk of CHD. The benefits of raloxifene in reducing the risks of invasive breast cancer and vertebral fracture should be weighed against the increased risks of venous thromboembolism and fatal stroke. (ClinicalTrials.gov number, NCT00190593 [ClinicalTrials.gov].).
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	The New England Journal of Medicine. - 355 : 2 (2006), p. 125-137. -
További szerzők:	Mosca, Lori Collins, Peter Geiger, Mary Jane Grady, Deborah Kornitzer, Marcel McNabb, Michelle A. Wenger, Nanette K. Czuriga István (1948-2018) (kardiológus) the Raloxifene Use for The Heart (RUTH) Trial Investigators
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM099099
Első szerző:	Bonaca, Marc P.
Cím:	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction / Bonaca Marc P., Bhatt Deepak L., Cohen Marc, Steg Philippe Gabriel, Storey Robert F., Jensen Eva C., Magnani Giulia, Bansilal Sameer, Fish M. Polly, Im Kyungah, Bengtsson Olof, Ophuis Ton Oude, Budaj Andrzej, Theroux Pierre, Ruda Mikhail, Hamm Christian, Goto Shinya, Spinar Jindrich, Nicolau José Carlos, Kiss Robert G., Murphy Sabina A., Wiviott Stephen D., Held Peter, Braunwald Eugene, Sabatine Marc S., PEGASUS-TIMI 54 Steering Committee and Investigators
Dátum:	2015
ISSN:	0028-4793
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	New England Journal Of Medicine. - 372 : 19 (2015), p. 1791-1800. -
További szerzők:	Bhatt, Deepak L. Cohen, Marc A. Steg, Philippe Gabriel Storey, Robert F. Jensen, Eva C. Magnani, Giulia Bansilal, Sameer Fish, M. Polly Im, Kyungah Bengtsson, Olof Ophuis, Ton Oude Budaj, Andrzej Theroux, Pierre Ruda, Mikhail Hamm, Christian Goto, Shinya Špinar, Jindrich Nicolau, José Carlos Kiss Róbert Gábor Murphy, Sabina A. Wiviott, Stephen D. Held, Peter Braunwald, Eugene Sabatine, Marc S. Jenei Csaba (1976-) (kardiológus) PEGASUS-TIMI 54 Steering Committee and Investigators
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM019413
Első szerző:	James, W. Philip
Cím:	Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects / James W. P., Caterson I. D., Coutinho W., Finer N., Van Gaal L. F., Maggioni A. P., Torp-Pedersen C., Sharma A. M., Shepherd G. M., Rode R. A., Renz C. L., for the SCOUT Investigators
Dátum:	2010
Megjegyzések:	The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established. METHODS: We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death). RESULTS: The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2/1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval [CI], 1.03 to 1.31; P=0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P=0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P=0.03). The rates of cardiovascular death and death from any cause were not increased. CONCLUSIONS: Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause. (Funded by Abbott; ClinicalTrials.gov number, NCT00234832.)
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	The New England Journal of Medicine. - 363 : 10 (2010), p. 905-917. -
További szerzők:	Caterson, Ian D. Coutinho, Walmir Finer, Nick Gaal, Luc, Van Maggioni, Aldo Torp-Pedersen, Christian Sharma, Arya Shepherd, Gillian Rode, Richard A. Renz, Cheryl L. Czuriga István (1948-2018) (kardiológus) for the SCOUT Investigators
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM029346
Cím:	Comparison of fondaparinux and enoxaparin in acute coronary syndromes / The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators
Dátum:	2006
ISSN:	0028-4793
Megjegyzések:	The combined use of anticoagulants, antiplatelet agents, and invasive coronary procedures reduces ischemic coronary events but also increases bleeding in patients with acute coronary syndromes. We therefore assessed whether fondaparinux would preserve the anti-ischemic benefits of enoxaparin while reducing bleeding. METHODS: We randomly assigned 20,078 patients with acute coronary syndromes to receive either fondaparinux (2.5 mg daily) or enoxaparin (1 mg per kilogram of body weight twice daily) for a mean of six days and evaluated death, myocardial infarction, or refractory ischemia at nine days (the primary outcome); major bleeding; and their combination. Patients were followed for up to six months. RESULTS: The number of patients with primary-outcome events was similar in the two groups (579 with fondaparinux [5.8 percent] vs. 573 with enoxaparin [5.7 percent]; hazard ratio in the fondaparinux group, 1.01; 95 percent confidence interval, 0.90 to 1.13), satisfying the noninferiority criteria. The number of events meeting this combined outcome showed a nonsignificant trend toward a lower value in the fondaparinux group at 30 days (805 vs. 864, P=0.13) and at the end of the study (1222 vs. 1308, P=0.06). The rate of major bleeding at nine days was markedly lower with fondaparinux than with enoxaparin (217 events [2.2 percent] vs. 412 events [4.1 percent]; hazard ratio, 0.52; P<0.001). The composite of the primary outcome and major bleeding at nine days favored fondaparinux (737 events [7.3 percent] vs. 905 events [9.0 percent]; hazard ratio, 0.81; P<0.001). Fondaparinux was associated with a significantly reduced number of deaths at 30 days (295 vs. 352, P=0.02) and at 180 days (574 vs. 638, P=0.05). CONCLUSIONS: Fondaparinux is similar to enoxaparin in reducing the risk of ischemic events at nine days, but it substantially reduces major bleeding and improves long term mortality and morbidity.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	The New England Journal of Medicine 354 : 14 (2006), p. 1464-1476. -
További szerzők:	Csiba László (1952-) (neurológus, pszichiáter) Édes István (1952-) (kardiológus) The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators
Internet cím:	DOI Intézményi repozitóriumban tárolt változat
Borító:
Saját polcon: